March, 08, 2020
Last week (3rd March 2020) we saw a firework on the Canadian NEO stock exchange: The IPO of the first pharmaceutical company focusing exclusively on psychedelic substances such as LSD, 18-MC (an Ibogaine derivative), broke all records! Demand was huge, leading to record trading volumes in the following few days, by those who were not involved in the pre-financing rounds.
As a pioneer in a completely new evolving sector, this new psychedelic stock brings an explosive price upside potential! The almost daily media reporting demonstrates an enormous interest. In the current weak stock market environment, investors naturally tend stocking up with the few potential winning ones. Our new stock pick has the potential to become an industry leader right from the start and is one of those rare ten-bagger opportunities! Since currently there is no serious competition, we consider the company a highly explosive mixture for massive gains.
In the following, we would like to share some research insights about this brand new evolving sector. You do not have to be a pharmaceutical expert or medical doctor to realize we are facing a real revolution in the multi-billion-dollar market here!
Some background on the brand new asset class of “Psychedelics stocks” – revolutionary therapeutic approaches with MDMA, 18-MC, LSD and Psilocybin
Indigenous cultures have used psychedelics for spiritual and medical purposes since time immemorial. Ayahuasca is used in some South American countries, whereas indigenous people use ibogaine in ceremonies in Africa. The substance ibogain is obtained from the plant of the African shrub called Tabernanthe iboga, which is known for its psychedelic properties. In the 1960s, Howard Lotsof discovered that the substance ibogaine clearly shows absence of any addictive effects. The benefits are twofold: improvement of side effects in subjects experiencing opiate withdrawal, as well as better prognosis in the treatment of substance abuse disorders for nicotine, methamphetamine, alcohol and other substance dependencies.
In the middle of the last century, western scientists and doctors began to investigate the therapeutic potential of mind-altering substances, also known as hallucinogens. In 1943, the Swiss chemist Albert Hoffmann discovered the hallucinogenic effects of LSD (lysergic acid diethylamide), a synthetic derivative of the ergot alkaloid lysergic acid. The scientists also focused on other substances such as psilocybin, the psychoactive ingredient in magic mushrooms. The uncontrolled recreational consumption of hallucinogens in the hippie era prompted the authorities to ban the previously freely available substances. As a result, research into psychedelics largely came to a standstill. Since the mid-1990s, numerous scientists around the world have again been intensively researching possible therapeutic areas of application of psychedelic substances. One of the pioneers in the field is the American research institute Johns Hopkins – Center for Psychedelic and Consciousness Research
Positive tests for psilocybin against various substance abuses
At Johns Hopkins Research Center, scientists study how psychedelics affect behavior, mood, cognition, and brain function. In the studies, the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), Lyme disease syndrome, anorexia nervosa and severe depression is examined.
“Johns Hopkins is deeply committed to exploring innovative treatments for our patients. Our scientists have shown that psychedelics have real potential as medicine, and this new center will help us explore that potential.”
– Paul B. Rothman, M.D., Dean of the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine.
New hope in various neurological disorders through psychedelic substances such as MDMA, 18-MC, LSD and Psilocybin
Neurogenic drugs can potentially reverse or compensate deficits and impairments related to neurological diseases and disorders, especially those related to the hippocampus.
The demand for alternative therapies and approaches to traditional psychotropic drugs is huge. Those affected hope for better tolerability and effectiveness, particularly with regard to the known side effects of depression and anxiety disorders. For some patients, conventional psychotropic drugs do not help to their full satisfaction. As several studies have shown, psychedelics may be able to fill this therapeutic gap. Further clinical studies based on empirically proven efficacy of psychedelic substances are required.
301 studies are planned or completed in the United States – the market potential is huge!
On the U.S. ClinicalTrials.gov website, U.S. The National Library of Medicine lists 301 clinical studies with the search term “Psychedelics”. The number of planned or completed studies on the active substance psilocybin alone is 39.
The effects of psychedelic drugs are being investigated in a number of clinical studies. The following disorders are subject of clinical research: treatment-resistant severe depression, anorexia, Alzheimer’s disease, obsessive-compulsive disorder, migraine, post-traumatic stress disorder, headache, substance addiction (e.g. opiates), anxiety disorders, ADHD in adults.
Leading researchers assume magic mushrooms could replace antidepressants in just five years. This will shake up the global market for $ 15 billion of antidepressants.
David Nutt, the UK government’s former chief drug advisor, is very optimistic about a favorable federal approval process. He announced last year, he expects psilocybin to be approved for the treatment of depression by 2027 at the very latest.
Depression is a big social problem. One in six Americans takes a psychiatric drug, such as an antidepressant. The World Health Organization estimates over 300 million people worldwide face this serious mental illness. Global antidepressant sales numbers are expected to explode to nearly $ 17 billion by 2020, and $ 150 billion is expected to be associated with treatment costs in the United States alone. These high numbers only include the direct medical costs such as therapy, medication and hospital stays, however does not take into consideration the negative effects on society.
Political acceptance in the US for alternative treatments and decriminalization of entheogen substances is growing fast
Currently in the United States, psychedelic substances such as LSD, MDMA, psilocybin and ibogaine but also cannabis are classified as a ‘Schedule 1 drug’ and are therefore prohibited at the federal level. However, the psychedelic reform movement is quietly progressing and four major cities are ready to offer suggestions to decriminalize entheogen substances (e.g. magic mushrooms).
Proponents in the American cities of Portland, Chicago, Berkeley and Dallas are pressing for decriminalization measures – either through the city council or through voting measures. The American city of Denver voted in May 2019 for decriminalization of magic mushrooms (which contain the psychedelic compound psilocybin).
For good reason, many investors are excited about the upcoming decriminalization wave that may resemble that of cannabis. However, we do not expect legalization of psychedelics for recreational use, rather medical use following strict rules and approvals of the pharmaceutical authorities, such as the FDA.
Here is the enormous potential for investors as well as innovative companies from the pharmaceutical industry / biotech sector. Various psychedelic substances such as MDMA, MC-18, LSD and psilocybin have a huge therapeutic potential for the treatment of various diseases.
Join from the beginning and benefit from a new mega trend! A completely new asset class is emerging
Pharmaceutical psychedelics stocks
Last week (3rd March 2020) we saw a firework on the Canadian NEO stock exchange: The IPO of the first pharmaceutical company focusing exclusively on psychedelic substances such as LSD, 18-MC (an Ibogaine derivative), broke all records! Demand was huge, leading to record trading volumes in the following few days, by those who were not involved in the pre-financing rounds. The fireworks in the stock calmed down somewhat on Friday and gave investors some time to take a deep breath.
In our view, this new psychedelics stock has explosive price potential! As a pioneer in a completely new evolving sector, this new psychedelic stock brings an explosive price upside potential! The almost daily media reporting demonstrates an enormous interest. In the current weak stock market environment, investors naturally tend stocking up with the few potential winning ones. Our new stock pick has the potential to become an industry leader right from the start and is one of those rare ten-bagger opportunities! Since currently there is no serious competition, we consider the company a highly explosive mixture for massive gains.
Take advantage on these insights and be the first to learn about the new investment opportunities in this revolutionary sector – we want you there right from the start!
In the following days, we will introduce you to the company and share our assessment of this new mega sector. Have you missed the huge chances of winning in the crypto and blockchain sector in the past? Were you late with lithium and cannabis? If this is the case, then likely you felt same way many investors felt as they missed the early access opportunity.
We are the first stock exchange bulletin covering the German speaking audience!
Subscribe and stay informed by increasing your chances for multi-bagger stock opportunities! In our next edition, you can read our analysis of the company introduction and psychedelic IPO.
Benefit from our unique network of brokers, analysts and industry experts and subscribe now our free newsletter!
Happy reading & investing!